This week we discuss the concept of "thought leaders" and we examine the conclusions about volume CT screening for lung cancer from the NELSON trial. We end with an interview with Dr. Sam Rubinstein, a hematology/oncology fellow at Vanderbilt University Medical Center, on his new paper published in JAMA Network Open titled "Indication of Measures of Uncertainty for Statistical Significance in Abstracts of Published Oncology Trials: A Systematic Review and Meta-analysis".

NELSON: doi.org/10.1056/NEJMoa1911793
Measures of Uncertainty: doi.org/10.1001/jamanetworkopen.2019.17530

Back us on Patreon! www.patreon.com/plenarysession

2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein

Download our free app to listen on your phone